Syntekabio to Promote Biopharmaceutical AI Drug Platform at 'PEGS Boston 2024'

ShinTekkaBio, an AI-based new drug development specialist company, announced that it will participate in the "20th Protein & Antibody Engineering Summit (PEGS) Boston" held from the 13th to the 17th of this month (local time), setting up an exhibition booth to promote its antibody discovery and cancer vaccine target discovery AI platforms.

PEGS Boston (Protein & Antibody Engineering Summit Boston) is a global R&D conference focusing on biopharmaceutical development, including antibody engineering. It is considered a major pharmaceutical industry event held annually in Boston, USA.

This year, the conference will be conducted in eight sessions covering engineering, anticancer drugs, multispecificity, immunotherapy, expression, analytical methods, immunogenicity, and therapeutics. Companies from around the world will operate exhibition booths and participate in networking.

ShinTekkaBio plans to set up an exhibition booth at this conference to promote and hold partnering meetings for its AI platform services, NEO-ARS® and Ab-ARS™.

NEO-ARS is an AI platform service that selects optimal cancer neoantigens for effective cancer vaccine development. At this conference, the company will unveil a version enhanced with a separate analysis simulation that evaluates patient coverage by combining various cancer-specific mutations. It is characterized by discovering target neoantigens that can be commonly used in the treatment of as many patients as possible and providing them to developers of off-the-shelf cancer vaccines.

ShinTekkaBio expects that immuno-oncology drug developers interested in both personalized and off-the-shelf cancer vaccine development will pay close attention to NEO-ARS.

Ab-ARS is an AI platform service that designs antigen-antibody binding sites (complementarity-determining regions, CDR) sequences. Using the three-dimensional structure formed by the epitope of the target antigen and the variable domain of the antibody as a template, it identifies the CDR amino acid sequences of antibodies optimized for antigen-antibody binding.

This service has the advantage of rapidly discovering antibody candidates that bind to the desired target antigen based on an automated workflow, thereby shortening the time required for antibody screening.

By participating in PEGS Boston, the company aims to promote its AI platforms NEO-ARS and Ab-ARS for biopharmaceutical development to the global market, demonstrating its biopharmaceutical development capabilities in addition to its AI platform DeepMatcher® for small molecule synthetic drug development.

Jongseon Jeong, CEO of ShinTekkaBio, said, “It is encouraging to showcase our AI new drug technology applicable to biopharmaceutical development at PEGS Boston 2024,” adding, “We are pleased to demonstrate to the global pharmaceutical and bio industries that ShinTekkaBio can collaborate not only in synthetic drugs but also in the biopharmaceutical field.”

He continued, “We believe we can discuss cooperation plans as we can meet the needs of companies seeking to develop immuno-oncology therapies or antibody therapeutics.”